Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 14 • N.4/2023
A parità di livelli plasmatici di colesterolo LDL, un elevato assorbimento ed una bassa sintesi di colesterolo sono associati ad un aumentato rischio cardiovascolare.
Data is limited on measures influencing cholesterol homeostasis in subjects at high risk of developing CVD relative to established risk factors. To address this, we quantified circulating indicators of cholesterol homeostasis (plasma phytosterols and cholesterol precursors concentrations as surrogate measures of cholesterol absorption and synthesis, respectively) in Framingham Offspring Study Cycle-6 participants diagnosed with established CVD and/or >50% carotid stenosis not taking lipid lowering medication (cases, N=155), and matched controls (N=414). Cases and controls had similar plasma LDL-cholesterol; HDL-cholesterol was significantly lower in males while triglyceride concentrations were significantly higher in female cases relative to their respective controls. Cholesterol absorption markers were significantly higher (229+/-7 vs.196+/-4, 169+/-6 vs.149+/-3 and 144+/-5 vs.135+/-3 for campesterol, sitosterol and cholestanol, respectively), whereas cholesterol synthesis markers were significantly lower (116+/-4 vs.138+/-3, 73+/-3 vs.75+/-2 for lathosterol and desmosterol, respectively) in cases compared to controls, irrespective of sex. After controlling for standard risk factors, campesterol (2.47[1.71-3.56]; P<0.0001], sitosterol (1.86[1.38-2.50]; P<0.0001), cholestanol (1.57[1.09-2.27]; P=0.02), desmosterol (0.59 [0.42-0.84]; P=0.003) and lathosterol (0.58[0.43-0.77]; P=0.0002) were significantly associated with CVD (odds ratio [95%CI]). These data suggest that impaired cholesterol homeostasis, reflected by lower synthesis and higher absorption marker concentrations, are highly significant independent predictors of prevalent CVD in this study population.
Modena, 22-23 Giugno 2023
[continua a leggere]Rivista in lingua italiana
riservata ai Soci SISA
Ultimo numero:
Anno 14 • N.4/2023
Rivista Italiana della
Ipercolesterolemia
Familiare Omozigote
Anno 5 • N.1/2023
Nuovo sito dedicato al Progetto LIPIGEN
Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina
PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina
Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)
E' necessario essere loggati come utente del Gruppo GILA per poter accedere
Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)
Pagina informativa per medici e pazienti